The GBM cell line, DBTRG-05MG (ATCCTM), was chosen for knockdowns due to the following reasons: (1) DBTRG-05MG cells acquire protection against VSV-I after 24 h IFNα treatment before infecting [49]; (2) this cell line proliferates significantly faster in comparison with patient-derived cells, allowing achievement of culture establishing in adequate times. The gene discussed is IFNA1; the disease is glioblastoma.